Tag: $Zealand Pharma A/S

Zealand Pharma on Thursday outlined an ambitious five-year strategy for its anti-obesity portfolio Thursday, spotlighting how growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more of these medicines near market entry.

Shares of Denmark’s Zealand Pharma popped nearly 23% in Friday morning deals, notching a record high after an early-stage study of its weight loss drug challenger produced positive results.

Shares of Denmark’s Zealand Pharma shot 32% higher in morning trade, after results showed success in its liver disease treatment survodutide, which is also on trial as a drug to treat obesity.